TY - JOUR
T1 - Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area
AU - Horgan, Denis
AU - Hamdi, Yosr
AU - Lal, Jonathan A.
AU - Nyawira, Teresia
AU - Meyer, Salomé
AU - Kondji, Dominique
AU - Francisco, Ngiambudulu M.
AU - De Guzman, Roselle
AU - Paul, Anupriya
AU - Bernard, Branka
AU - Reddy Nallamalla, Krishna
AU - Park, Woong Yang
AU - Triapthi, Vijay
AU - Tripathi, Ravikant
AU - Johns, Amber
AU - Singh, Mohan P.
AU - Phipps, Maude E.
AU - Dube, France
AU - Rasheed, Hadi Mohamad Abu
AU - Kozaric, Marta
AU - Pinto, Joseph A.
AU - Doral Stefani, Stephen
AU - Aponte Rueda, Maria Eugenia
AU - Fujita Alarcon, Ricardo
AU - Barrera-Saldana, Hugo A.
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/2
Y1 - 2023/2
N2 - Radical new possibilities of improved treatment of cancer are on offer from an advanced medical technology already demonstrating its significance: next-generation sequencing (NGS). This refined testing provides unprecedentedly precise diagnoses and permits the use of focused and highly personalized treatments. However, across regions globally, many cancer patients will continue to be denied the benefits of NGS as long as some of the yawning gaps in its implementation remain unattended. The challenges at the regional and national levels are linked because putting the solutions into effect is highly dependent on cooperation between regional- and national-level cooperation, which could be hindered by shortfalls in interpretation or understanding. The aim of the paper was to define and explore the necessary conditions for NGS and make recommendations for effective implementation based on extensive exchanges with policy makers and stakeholders. As a result, the European Alliance for Personalised Medicine (EAPM) developed a maturity framework structured around demand-side and supply-side issues to enable interested stakeholders in different countries to self-evaluate according to a common matrix. A questionnaire was designed to identify the current status of NGS implementation, and it was submitted to different experts in different institutions globally. This revealed significant variability in the different aspects of NGS uptake. Within different regions globally, to ensure those conditions are right, this can be improved by linking efforts made at the national level, where patients have needs and where care is delivered, and at the global level, where major policy initiatives in the health field are underway or in preparation, many of which offer direct or indirect pathways for building those conditions. In addition, in a period when consensus is still incomplete and catching up is needed at a political level to ensure rational allocation of resources—even within individual countries—to enable the best ways to make the necessary provisions for NGS, a key recommendation is to examine where closer links between national and regional actions could complement, support, and mutually reinforce efforts to improve the situation for patients.
AB - Radical new possibilities of improved treatment of cancer are on offer from an advanced medical technology already demonstrating its significance: next-generation sequencing (NGS). This refined testing provides unprecedentedly precise diagnoses and permits the use of focused and highly personalized treatments. However, across regions globally, many cancer patients will continue to be denied the benefits of NGS as long as some of the yawning gaps in its implementation remain unattended. The challenges at the regional and national levels are linked because putting the solutions into effect is highly dependent on cooperation between regional- and national-level cooperation, which could be hindered by shortfalls in interpretation or understanding. The aim of the paper was to define and explore the necessary conditions for NGS and make recommendations for effective implementation based on extensive exchanges with policy makers and stakeholders. As a result, the European Alliance for Personalised Medicine (EAPM) developed a maturity framework structured around demand-side and supply-side issues to enable interested stakeholders in different countries to self-evaluate according to a common matrix. A questionnaire was designed to identify the current status of NGS implementation, and it was submitted to different experts in different institutions globally. This revealed significant variability in the different aspects of NGS uptake. Within different regions globally, to ensure those conditions are right, this can be improved by linking efforts made at the national level, where patients have needs and where care is delivered, and at the global level, where major policy initiatives in the health field are underway or in preparation, many of which offer direct or indirect pathways for building those conditions. In addition, in a period when consensus is still incomplete and catching up is needed at a political level to ensure rational allocation of resources—even within individual countries—to enable the best ways to make the necessary provisions for NGS, a key recommendation is to examine where closer links between national and regional actions could complement, support, and mutually reinforce efforts to improve the situation for patients.
KW - NGS
KW - adoption
KW - availability
KW - framework
KW - maturity framework
KW - molecular tumour board
KW - next-generation sequencing
KW - policy makers
KW - reimbursement
KW - survey
UR - https://www.scopus.com/pages/publications/85147801247
U2 - 10.3390/healthcare11030431
DO - 10.3390/healthcare11030431
M3 - Article
AN - SCOPUS:85147801247
SN - 2227-9032
VL - 11
JO - Healthcare (Switzerland)
JF - Healthcare (Switzerland)
IS - 3
M1 - 431
ER -